Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 19, 2023 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days

MOUNTAIN VIEW, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
April 13, 2023 16:05 ET | Source: IGM Biosciences, Inc.

IGM Biosciences Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2023

MOUNTAIN VIEW, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
March 30, 2023 16:05 ET | Source: IGM Biosciences, Inc.

IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

– Encouraging initial data from IGM-8444 combination with FOLFIRI; first patient dosed in randomized trial – – Imvotamab to move forward into clinical studies in multiple autoimmune diseases – –...
March 27, 2023 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023

MOUNTAIN VIEW, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
February 02, 2023 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference

MOUNTAIN VIEW, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
January 17, 2023 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors

MOUNTAIN VIEW, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
January 09, 2023 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

– Initial Data from Phase 1 combination with FOLFIRI shows promising activity in heavily pretreated metastatic colorectal cancer patients – – Encouraging safety profile in combination with FOLFIRI...
January 03, 2023 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today...
December 11, 2022 10:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting

MOUNTAIN VIEW, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today...
December 01, 2022 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference

MOUNTAIN VIEW, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today...